Dr. Susan Galbraith

I really don't think that there's a concern about long-term side effects from this.

I think it's an acute event which, if appropriately treated, is possible to fully recover from for the vast majority of patients.

Yeah.

So again, the key endpoint here is the invasive disease-free survival.

That's the primary endpoint in this study.

Again, and on that endpoint, we saw a 53% reduction in the improvement in the invasive disease-free survival rate, which is really very clinically meaningful.

And this leads to a really important delta in the two-year and three-year landmark rates.

Again, we will continue to monitor this and see that, you know, follow up.

But, you know, what I would say is that this is an impressive effect size and people were very impressed with the data.

It's one of the reasons why it got a presidential session and, you know, very good commentary following the presentation of the data.

So what I would say is that, first of all, NHERTU has shown activity in patients with active brain metastases.

It's impressive.

And also in the metastatic settings, we have seen a good activity against the time until patients actually develop brain metastases.

So I would expect that

with time we can have a look at those effects in these early stage studies as well and have a look at that because we know that this drug actually works in those settings and I think the reason why it works is because of the bystander effect that you get within HER2

So you have this cleavable linker and then the payload, the droxtacan payload actually can diffuse across the cell membrane.

So even if there is uneven disruption of the blood-brain barrier within a brain metastasis, you will get this bystander effect and spread to surrounding cells.

And I think that's one of the reasons why we're seeing good activity

in patients with brain metastases.

So you'd expect to see it over time.